Linnaeus Therapeutics is happy to announce that 2 cohorts have recently been opened in their ongoing clinical trial for the treatment of metastatic uveal melanoma patients following early promising data in this indication.  Patients who qualify for the study must have metastatic uveal melanoma and not have had prior anti-PD-1 therapy. If enrolled they will be randomized to receive LNS8801 alone or in combination with anti-PD-1 therapy.  LNS8801 is an oral tablet given once daily.  The anti-PD-1 therapy is an intravenous infusion given every 3 weeks.  

Interested patients should contact their nearest trial site: Yale Cancer Center in New Haven, CT; Massachusetts General Hospital in Boston, MA; Thomas Jefferson University, Sidney Kimmel Cancer Center in Philadelphia, PA; University of Pennsylvania Hospital in Philadelphia, PA; Cedars-Sinai Medical Center in Los Angeles, CA; University of New Mexico Comprehensive Cancer Center in Albuquerque, NM; MD Anderson Cancer Center in Houston, TX; and The START Center for Cancer Care in San Antonio, TX.

Additional information on the trial may be found by looking up trial NCT04130516 on clinicaltrials.gov.